Webinar: Development of New Drugs for Dementia - Current Status and Outlook
After decades of stagnating research, there's renewed momentum: new monoclonal antibodies against amyloid deposits, such as Lecanemab or Donanemab, are directly targeting the disease mechanisms of Alzheimer's dementia for the first time. Previous medications could only alleviate symptoms, but not slow the progression of the disease. How promising are the new drugs – and…
